Table 2.
Baseline clinical characteristics of HIV infected patients enrolled in UTT and differed programs in Gurage Zone, 2019
| Variables | Outcome by Program | ||||
|---|---|---|---|---|---|
| UTT (N, %) | CD4 based (N, %) | Total | |||
| TB | NO TB | TB | NO TB | (N, %) | |
| WHO stage | |||||
| Stage I | 0 (0) | 38 (31.1) | 3 (9.1) | 48 (21.5) | 89 (23.1) |
| Stage II | 1 (16.7) | 38 (31.1) | 5 (15.3) | 53 (23.8) | 97 (25.2) |
| Stage III | 3 (50) | 40 (32.8) | 22 (66.7) | 115 (51.5) | 180 (47) |
| Stage IV | 2 (33.3) | 6 (4.9) | 3 (9) | 7 (3.2) | 18 (4.7) |
| Median CD4 count | 262.4 (IQR: 130–568) | 181 (IQR: 110–235) | 201 (IQR: 126–303) | ||
| Mean weight | 52.5+ 2 | 51 + 9 | 52.3+ 11.3 | ||
| Median time to Rx | 0.3 (IQR = 0.1–4.2) | 0.9 (IQR = 0.6–1.6) | 0.7 (IQR = 0.2–1.2) | ||
| OIS before ART | |||||
| Yes | 3 (50) | 49 (40.2) | 22 (66.7) | 116 (52) | 190 (49.5) |
| No | 3 (50) | 73 (59.8) | 11 (33.3) | 107 (48) | 194 (50.5) |
| IPT | |||||
| Yes | 4 (66.7) | 113 (92.6) | 11 (33.3) | 155 (69.5) | 283 (73.7) |
| No | 2 (33.3) | 9 (7.4) | 22 (66.7) | 68 (30.5) | 101 (26.3) |
| Treatment failure | |||||
| Yes | 3 (50) | 9 (7.4) | 2 (6) | 6 (2.7) | 20 (5.2) |
| No | 3 (50) | 113 (92.6) | 31 (94) | 217 (97.3) | 364 (94.8) |
IPT Isoniazid preventive therapy, RX Treatment